Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase
The preferred route of administration for an injected therapeutic agent is subcutaneous (SC), but SC injections are generally limited to no more than 1-2 mL in volume, representing a major challenge, especially for large protein biologics.


Pharmaceutical Technology


2. J. Prettyman, "Subcutaneous or Intramuscular? Confronting a Parenteral Administration Dilemma," Medsurg. Nursing, 14 (2), 93–98 (2005).

3. H.C. Ansel, L.V. Allen, and N.G. Popovich, Pharmaceutical Dosage Forms and Drug Delivery Systems (Lippincott Williams & Wilkins, Philadelphia, PA, 8th ed., 2004).

4. A.L. Alcantara et al.,"Radiologic Study of Injection Drug Use Complications," Infect. Dis. Clin. North Am. 16 (3), 713–743 (2002).

5. P.D. Brown and J.R. Ebright, "Skin and Soft Tissue Infections in Injection Drug Users," Curr. Infect. Dis. Rep. 4 (5), 415–419 (2002).

6. S. Satyanarayana and A.D. Mathur, "Atypical Mycobacterial Injection Abscess," J. Indian Med. Assoc. 101 (1), 36–40 (2003).

7. S.C. DeWitt, Fundamental Concepts and Skills for Nursing (WB Saunders Company, Philadelphia, PA, 2001).

8. P.S. Bergeson, S.A. Singer, and A.M. Kaplan, "Intramuscular Injections in Children," Pediatrics 70 (6), 944–948 (1982).

9. A. Supersaxo, W.R. Hein, and H. Steffen, "Effect of Molecular Weight on the Lymphatic Absorption of Water-soluble Compounds Following Subcutaneous Administration," Pharm. Res. 7 (2), 167–179 (1990).

10. Campath (alemtuzumab) Package Insert, Bayer Healthcare Pharmaceuticals, Wayne, NJ, Jan. 2007.

11. M.C. Hochberg et al., "Comparison of the Efficacy of the Tumor Necrosis Factor α-Blocking Agents Adalimumab, Etanercept, and Infliximab When Added to Methotrexate in Patients with Active Rheumatoid Arthritis," Ann. Rheum. Dis. 62 (suppl 2), ii13–ii16 (2003).

12. E. Nemser and D. Azad, "Assessing the Impact of Differential Reimbursement of Medicare Pharmacy Benefits," Biotechnology Healthcare, Aug. 47–51 (2005).

13. T.D. Day, "The Permeability of Extracellular Connective Tissue and the Nature of the Interfibrillary Substance," J. Physiol. 117 (1), 1–8 (1952).

14. A.H. Paes, A. Bakker, and C.J. Soe-Agnie, "Impact of Dosage Frequency on Patient Compliance," Diabetes Care 20 (10), 1512–1517 (1997).

15. G.I Frost, "Recombinant Human Hyaluronidase (rHuPH20): An Enabling Platform for Subcutaneous and Fluid Administration," Expert Opin. Drug. Del. 4 (4), 427–440 (2007).

16. N. Verzijl et al., "Effect of Collagen Turnover on the Accumulation of Advanced Glycation End Products," J. Biol. Chem. 15 (50), 39027–39031 (2000).

17. U.B.G. Laurent, L.B. Dahl, and P.K. Reed, "Catabolism of Hyaluronan in Rabbit Skin Takes Place Locally in Lymph Nodes and Liver," Exp. Physiol. 76 (5), 695–703 (1991).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here